Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.82 |
| ▸ | AKT2 | P31751 | 20/20 | 0.82 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.72 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390637 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3948393 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16617460 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17424856 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191650 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL193125 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191301 | 0.89 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192866 | 0.89 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191789 | 0.89 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191788 | 0.89 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3656764-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| EP-2858989-B9 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3719014-A1 | SOLID FORMS OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3656764-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-2858989-B1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20150064171-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140256691-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140155372-A1 | COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2694485-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012135750-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256691-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE | AKT2, CYP17A1, AKT1 | AKT1 3/4885AKT2 1/4885AKT3 6/4885 |
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20150064171-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE | AKT1, AKT2, PIK3CA | AKT1 1/4885AKT2 2/4885AKT3 5/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20140155372-A1 | COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE | PDPK1, MAPK1, MAPK9 | AKT1 18/4885AKT2 15/4885AKT3 10/4885 |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.